These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36210036)

  • 1. Existing and emerging mitigation strategies for the prevention of accidental overdose from oral pharmaceutical products.
    Murshed M; Salim M; Boyd BJ
    Eur J Pharm Biopharm; 2022 Nov; 180():201-211. PubMed ID: 36210036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
    Bannwarth B
    Drugs; 2012 Sep; 72(13):1713-23. PubMed ID: 22931520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice.
    Lee YH; Brown DL; Chen HY
    Pain Physician; 2017 Nov; 20(7):E1003-E1023. PubMed ID: 29149148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study.
    Larance B; Dobbins T; Peacock A; Ali R; Bruno R; Lintzeris N; Farrell M; Degenhardt L
    Lancet Psychiatry; 2018 Feb; 5(2):155-166. PubMed ID: 29336948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
    Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
    Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of prodrug technology and its application for developing abuse-deterrent opioids.
    Gudin JA; Nalamachu SR
    Postgrad Med; 2016 Jan; 128(1):97-105. PubMed ID: 26615852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. System dynamics modeling as a potentially useful tool in analyzing mitigation strategies to reduce overdose deaths associated with pharmaceutical opioid treatment of chronic pain.
    Wakeland W; Schmidt T; Gilson AM; Haddox JD; Webster LR
    Pain Med; 2011 Jun; 12 Suppl 2():S49-58. PubMed ID: 21668757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?
    Schneider JP; Matthews M; Jamison RN
    CNS Drugs; 2010 Oct; 24(10):805-10. PubMed ID: 20839893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
    Webster LR; Markman J; Cone EJ; Niebler G
    Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone.
    Nalamachu S; Kopecky EA; Taylor R; Vaughn B; O'Connor M
    Curr Med Res Opin; 2016 Jul; 32(7):1311-7. PubMed ID: 27025986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Hot Melt Extrusion Technology in the Development of Abuse-Deterrent Formulations: An Overview.
    Butreddy A; Nyavanandi D; Narala S; Austin F; Bandari S
    Curr Drug Deliv; 2021; 18(1):4-18. PubMed ID: 32811398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
    Rauck RL
    Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
    Gasior M; Bond M; Malamut R
    Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse-deterrent formulations: part 2: commercial products and proprietary technologies.
    Mastropietro DJ; Omidian H
    Expert Opin Pharmacother; 2015 Feb; 16(3):305-23. PubMed ID: 25421961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics.
    Cohen JP; Mendoza M; Roland C
    Clin Ther; 2018 Feb; 40(2):334-344. PubMed ID: 29398162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioids with abuse-deterrent properties: A regulatory and technological overview.
    Haddox JD
    J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.
    Park K; Otte A
    Annu Rev Biomed Eng; 2019 Jun; 21():61-84. PubMed ID: 30786212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abuse-deterrent opioids: an update on current approaches and considerations.
    Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
    Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Abuse deterrent drug formulations for opioids].
    Matter M; Mühlebach S; Puchkov M; Huwyler J
    Ther Umsch; 2020; 77(1):24-28. PubMed ID: 32486991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.